Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Abexinostat follicular lymphoma not applicable detail...
Unknown unknown Copanlisib follicular lymphoma not applicable detail...
Unknown unknown Ublituximab + Umbralisib follicular lymphoma not applicable detail...
Unknown unknown Bendamustine + Bortezomib + Rituximab follicular lymphoma not applicable detail...
EZH2 positive Tazemetostat follicular lymphoma predicted - sensitive detail...
Unknown unknown Ocaratuzumab follicular lymphoma not applicable detail...
Unknown unknown CPI-0610 follicular lymphoma not applicable detail...
Unknown unknown Bendamustine + Obinutuzumab follicular lymphoma not applicable detail...
Unknown unknown Rituximab follicular lymphoma not applicable detail...
Unknown unknown Ibrutinib + Venetoclax follicular lymphoma not applicable detail...
Unknown unknown Bendamustine + Veliparib follicular lymphoma not applicable detail...
Unknown unknown Bendamustine + Rituximab + Veliparib follicular lymphoma not applicable detail...
Unknown unknown Umbralisib follicular lymphoma not applicable detail...
Unknown unknown Buparlisib + Ibrutinib follicular lymphoma not applicable detail...
Unknown unknown Hu5F9-G4 + Rituximab follicular lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00577278 Phase II Ibritumomab Sirolimus + Tacrolimus + Methotrexate Rituximab Fludarabine + Melphalan Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma Active, not recruiting
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated
NCT01216683 Phase II Bendamustine + Rituximab Bortezomib Lenalidomide Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Active, not recruiting
NCT01286272 Phase II Bendamustine + Ofatumumab Bendamustine + Bortezomib + Ofatumumab Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Active, not recruiting
NCT01307267 Phase I Utomilumab + Rituximab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed
NCT01691898 Phase Ib/II Obinutuzumab + Pinatuzumab Vedotin + Rituximab Polatuzumab Vedotin + Pinatuzumab Vedotin + Rituximab Obinutuzumab + Polatuzumab Vedotin A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS) Active, not recruiting
NCT01719250 Phase I Buparlisib Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed
NCT01732913 Phase III Idelalisib Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated
NCT01732926 Phase III Idelalisib Bendamustine + Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated
NCT01796171 Phase Ib/II Lilotomab Betalutin Rituximab A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) Recruiting
NCT01804686 Phase III Ibrutinib A Long-term Extension Study of PCI-32765 (Ibrutinib) Enrolling by invitation
NCT01897012 Phase I romidepsin Alisertib Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Completed
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Active, not recruiting
NCT01955499 Phase I Ibrutinib + lenalidomide Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting
NCT01974440 Phase III Ibrutinib Bendamustine + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma Active, not recruiting
NCT01976585 Phase Ib/II CDX-301 + poly ICLC In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy Recruiting
NCT01994382 Phase I Cerdulatinib Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma Recruiting
NCT02038946 Phase II Nivolumab Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) Active, not recruiting
NCT02049541 Phase I BKM120 + Rituximab Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma Active, not recruiting
NCT02082977 Phase I GSK126 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma Terminated
NCT02106091 Phase I AFM11 Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL Suspended
NCT02187861 Phase II Bendamustine + Rituximab Bendamustine + GDC-0199 + Rituximab GDC-0199 + Rituximab A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma Completed
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed
NCT02220842 Phase I Atezolizumab + Obinutuzumab A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma Active, not recruiting
NCT02254772 Phase Ib/II Ipilimumab + SD-101 TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma Completed
NCT02257567 Phase Ib/II Bendamustine + Rituximab Polatuzumab Vedotin Obinutuzumab A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Recruiting
NCT02266147 Phase Ib/II SD-101 Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma Completed
NCT02282358 Phase Ib/II Mocetinostat Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Active, not recruiting
NCT02339922 Phase II Ixazomib + Rituximab Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Recruiting
NCT02343536 Phase I Cyclophosphamide + Prednisone + Rituximab + Vincristine Azacitidine A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma Active, not recruiting
NCT02348216 Phase Ib/II KTE-C19 A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) Recruiting
NCT02367040 Phase III Rituximab Copanlisib Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) Recruiting
NCT02369016 Phase III Copanlisib Phase III Copanlisib in Rituximab-refractory iNHL Active, not recruiting
NCT02376699 Phase I Pembrolizumab + SEA-CD40 SEA-CD40 Safety Study of SEA-CD40 in Cancer Patients Active, not recruiting
NCT02381080 Phase I Erythromycin + Ibrutinib + Voriconazole Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy Completed
NCT02384954 Phase Ib/II ALT-803 + Rituximab ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab Recruiting
NCT02401048 Phase Ib/II Ibrutinib + MEDI4736 A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas Active, not recruiting
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated
NCT02446457 Phase II Pembrolizumab + Rituximab Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma Active, not recruiting
NCT02454270 Phase II JNJ-64052781 A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies Terminated
NCT02471911 Phase I Dexamethasone Carboplatin + Etoposide + Ifosfamide + Rituximab Selinexor KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma Recruiting
NCT02501473 Phase Ib/II GLA-SE + Pembrolizumab Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab With Follicular Non-Hodgkin's Lymphoma Recruiting
NCT02532192 Phase I Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma Withdrawn
NCT02532257 Phase II Rituximab + Lenalidomide + Ibrutinib Study of Ibrutinib in Combination With Rituximab and Lenalidomide Active, not recruiting
NCT02536300 Phase III Idelalisib Dose Optimization Study of Idelalisib in Follicular Lymphoma Recruiting
NCT02564744 Phase II Debio 1562 + Rituximab Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL Recruiting
NCT02576275 Phase III Bendamustine + Rituximab Duvelisib A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) Withdrawn
NCT02596971 Phase I Atezolizumab + Obinutuzumab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Bendamustine Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma Active, not recruiting
NCT02600897 Phase Ib/II lenalidomide + Obinutuzumab + Polatuzumab Vedotin A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT02603445 Phase I BCL201 + Idelalisib Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL Completed
NCT02605694 Phase II Duvelisib + Rituximab CHOP + Rituximab Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) Withdrawn
NCT02611323 Phase Ib/II Obinutuzumab + Polatuzumab Vedotin + Venetoclax A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT02624986 Phase Ib/II Idasanutlin + Obinutuzumab A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting
NCT02626455 Phase III Vincristine Prednisone Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine Copanlisib Bendamustine + Rituximab Rituximab Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) Recruiting
NCT02631044 Phase I JCAR017 Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) Recruiting
NCT02631577 Phase I Atezolizumab + lenalidomide + Obinutuzumab A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma Active, not recruiting
NCT02650999 Phase Ib/II Pembrolizumab Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas Unknown status
NCT02700022 Phase I Alisertib R-EPOCH A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas Terminated
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep Recruiting
NCT02729896 Phase Ib/II Atezolizumab + Obinutuzumab + Polatuzumab Vedotin A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting
NCT02743546 Phase I Ibrutinib + JNJ-64052781 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma Withdrawn
NCT02747043 Phase III ABP 798 Rituximab Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE) Active, not recruiting
NCT02756247 Phase I Buparlisib + Ibrutinib A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma Active, not recruiting
NCT02776813 Phase I ACTR087 + Rituximab Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Recruiting
NCT02869633 Phase II Ibrutinib Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant Recruiting
NCT02900716 Phase I DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas Recruiting
NCT02914938 Phase I ME-401 ME-401 + Rituximab A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Recruiting
NCT02927964 Phase Ib/II Ibrutinib + SD-101 + Radiotherapy TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma Recruiting
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Recruiting
NCT02947347 Phase III Ibrutinib Ibrutinib + Rituximab Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma Recruiting
NCT02950220 Phase I Pembrolizumab + Ibrutinib Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting
NCT02953509 Phase Ib/II Hu5F9-G4 + Rituximab Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Recruiting
NCT02956382 Phase Ib/II Ibrutinib + Venetoclax Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma Recruiting
NCT02966730 Phase I Ibrutinib Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy Recruiting
NCT02992522 Phase I Lenalidomide + Obinutuzumab + Venetoclax Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Recruiting
NCT03010358 Phase Ib/II Entospletinib + Obinutuzumab Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Recruiting
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Recruiting
NCT03019640 Phase II BEAM + Lenalidomide + Filgrastim + Rituximab Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma Recruiting
NCT03039114 Phase I Bendamustine + INCB050465 + Obinutuzumab Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) Active, not recruiting
NCT03105336 Phase II KTE-C19 A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5) Recruiting
NCT03113422 Phase II Obinutuzumab GDC-0199 + Obinutuzumab Bendamustine + Obinutuzumab + Venetoclax Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (PrE0403) Recruiting
NCT03121677 Phase I Nivolumab + poly ICLC + Rituximab Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma Recruiting
NCT03126019 Phase II INCB050465 Idelalisib An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203) Recruiting
NCT03133221 Phase II Idelalisib 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Recruiting
NCT03135262 Phase Ib/II Idasanutlin + Rituximab + Venetoclax Idasanutlin + Obinutuzumab + Venetoclax Idasanutlin + Obinutuzumab + Rituximab + Venetoclax A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting
NCT03150329 Phase I Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma Recruiting
NCT03153462 Expanded access KTE-C19 + Fludarabine phosphate + Cyclophosphamide Axicabtagene Ciloleucel Expanded Access Study Available
NCT03156114 Phase I BI 754091 BI 754111 This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. Recruiting
NCT03178201 Phase II Umbralisib TGR1202 in Relapsed and Refractory Follicular Lymphoma Recruiting
NCT03179930 Phase II Entinostat + Pembrolizumab Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas Recruiting
NCT03189836 Phase I ACTR707 + Rituximab Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Recruiting
NCT03198026 Phase II Ibrutinib + Obinutuzumab Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas Recruiting
NCT03269669 Phase II Obinutuzumab + CHOP Lenalidomide + Obinutuzumab Obinutuzumab + Umbralisib Prednisone Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Recruiting
NCT03297424 Phase Ib/II PLX2853 A Study of PLX2853 in Advanced Malignancies. Recruiting
NCT03321643 Phase I Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab Atezolizumab + Rituximab Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma Recruiting
NCT03332017 Phase II BGB-3111 + Obinutuzumab Obinutuzumab A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma Recruiting
NCT03357627 Phase I TAK-659 + Venetoclax A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma Recruiting
NCT03379493 Phase I Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma Terminated
NCT03401853 Phase II Pembrolizumab + Rituximab Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma Recruiting
NCT03424122 Phase I Ibrutinib + INCB050465 Bendamustine + INCB050465 + Rituximab INCB050465 + Rituximab INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Recruiting
NCT03424603 Phase I STRO-001 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Recruiting
NCT03460977 Phase I PF-06821497 PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting
NCT03465891 Phase II Atezolizumab Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma Recruiting
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Recruiting
NCT03498612 Phase II Pembrolizumab Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Recruiting
NCT03547115 Phase I Voruciclib A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies Recruiting
NCT03568461 Phase II Tisagenlecleucel Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA) Recruiting
NCT03579927 Phase Ib/II Filgrastim iC9/CAR.19/IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Not yet recruiting
NCT03600441 Phase II Abexinostat Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER) Recruiting
NCT03610724 Phase II Tisagenlecleucel Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA) Recruiting
NCT03636503 Phase I Avelumab + Rituximab + Utomilumab Avelumab + PF-04518600 + Rituximab PF-04518600 + Rituximab + Utomilumab RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA Recruiting
NCT03671018 Phase I CHOP + Rituximab Cyclophosphamide + Prednisone + Rituximab + Vincristine Bendamustine + Polatuzumab Vedotin + Rituximab Bendamustine + Obinutuzumab BTCT4465A + Polatuzumab Vedotin BTCT4465A Obinutuzumab Tocilizumab A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Recruiting
NCT03685344 Phase I Durvalumab + Loncastuximab tesirine Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma Recruiting
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Not yet recruiting
NCT03768505 Phase II ME-401 Study of ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies Recruiting
NCT03779113 Phase Ib/II HMPL-523 An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma Recruiting
NCT03789240 Phase II Copanlisib + Rituximab Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma Not yet recruiting